Biodesix to buy U.S. lab, lung nodule test from Oncimmune
The deal, which would become effective Nov. 1, is valued at up to $28 million over the next five years. Biodesix will acquire the UK company's US lab in Kansas.
Biodesix acquires Seattle-based developer of blood-based lung nodule test
Acquisition of Integrated Diagnostics gives Biodesix control of test to determine if nodules are benign or malignant.
The Power Behind Enterprise EHR Software for Large Healthcare Systems
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.